Earnings ·
Evolus, Inc. reported second quarter 2026 financial results with total net revenues of $84.1 million, a 21% increase…
EOLSEvolus, Inc.
Evolus, Inc. reported second quarter 2026 financial results with total net revenues of $84.1 million, a 21% increase year-over-year. The company achieved positive Adjusted EBITDA of $4.7 million for the third consecutive quarter, marking a $12.6 million improvement over the prior year period. Evolus raised its full-year 2026 net revenue guidance to between $330 million and $337 million and narrowed non-GAAP operating expense guidance to between $212 million and $216 million. The company also announced an exclusive U.S. licensing agreement with IBSA for Profhilo, a skin quality injectable expected to generate peak annual revenue exceeding $100 million upon commercialization in 2030. Additionally, Evolus expanded its Estyme franchise into Canada, Australia, and New Zealand. The company operates in the aesthetic injectables industry, developing and marketing neurotoxins and hyaluronic acid gels.